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Summary
Background Lowering of LDL cholesterol reduces major vascular events, but whether more intensive therapy safely 
produces extra beneﬁ ts is uncertain. We aimed to establish eﬃ  cacy and safety of more intensive statin treatment in 
patients at high cardiovascular risk.
Methods We undertook a double-blind randomised trial in 12 064 men and women aged 18–80 years with a history of 
myocardial infarction. Participants were either currently on or had clear indication for statin therapy, and had a total 
cholesterol concentration of at least 3·5 mmol/L if already on a statin or 4∙5 mmol/L if not. Randomisation to either 
80 mg or 20 mg simvastatin daily was done centrally using a minimisation algorithm. Participants were assessed at 2, 4, 
8, and 12 months after randomisation and then every 6 months until ﬁ nal follow-up. The primary endpoint was major 
vascular events, deﬁ ned as coronary death, myocardial infarction, stroke, or arterial revascularisation. Analysis was by 
intention to treat. This study is registered, number ISRCTN74348595.
Findings 6031 participants were allocated 80 mg simvastatin daily, and 6033 allocated 20 mg simvastatin daily. During 
a mean follow-up of 6∙7 (SD 1·5) years, allocation to 80 mg simvastatin produced an average 0∙35 (SE 0·01) mmol/L 
greater reduction in LDL cholesterol compared with allocation to 20 mg. Major vascular events occurred in 
1477 (24·5%) participants allocated 80 mg simvastatin versus 1553 (25·7%) of those allocated 20 mg, corresponding 
to a 6% proportional reduction (risk ratio 0∙94, 95% CI 0∙88–1∙01; p=0∙10). There were no apparent diﬀ erences in 
numbers of haemorrhagic strokes (24 [0·4%] vs 25 [0·4%]) or deaths attributed to vascular (565 [9·4%] vs 572 [9·5%]) 
or non-vascular (399 [6·6%] vs 398 [6·6%]) causes. Compared with two (0·03%) cases of myopathy in patients taking 
20 mg simvastatin daily, there were 53 (0·9%) cases in the 80 mg group.
Interpretation The 6% (SE 3·5%) reduction in major vascular events with a further 0·35 mmol/L reduction in LDL 
cholesterol in our trial is consistent with previous trials. Myopathy was increased with 80 mg simvastatin daily, but 
intensive lowering of LDL cholesterol can be achieved safely with other regimens.
Funding Merck; The Clinical Trial Service Unit also receives funding from the UK Medical Research Council and the 
British Heart Foundation.
Introduction
LDL cholesterol is an important cause of coronary heart 
disease. Observational studies indicate a continuous 
positive association between risk of coronary heart disease 
and LDL cholesterol concentration that extends throughout, 
and well below, the range seen in high-income 
populations.1,2 Taken together, several large randomised 
trials of statin therapy versus control have shown that 
lowering of LDL cholesterol reduces risk of occlusive 
vascular events.3 Beneﬁ ts were seen even in participants 
who, before randomisation, had lower-than-average 
cholesterol concentrations, and the proportional risk 
reduction was related to the magnitude of the achieved 
cholesterol reduction.3,4 These ﬁ ndings suggest indirectly 
that larger reductions in LDL cholesterol would produce 
larger reductions in the risk of vascular events.
Previously, four randomised trials have directly compared 
the eﬀ ects on clinical endpoints of more versus less potent 
statin regimens.5–8 Collectively, the results of those trials 
suggest that more intensive lowering of  LDL cholesterol 
produces further reductions in vascular events,9 but 
concerns remain about the possibility of signiﬁ cant adverse 
eﬀ ects.10 Moreover, high doses of particular statins have 
been associated with increases in liver enzyme 
concentrations and with increases in the rare but potentially 
serious side-eﬀ ect of myopathy.5–8 In the SEARCH trial, we 
aimed to help establish reliably the balance of eﬃ  cacy and 
safety of more intensive LDL-cholesterol-lowering therapy 
by comparing long-term treatment with 80 mg versus 
20 mg simvastatin daily in a large population of patients at 
high risk of cardiovascular events. 
Methods
Patients
The study objectives, design, and methods have been 
reported previously,11,12 and are summarised here. Men 
and women aged 18–80 years with a history of previous 
myocardial infarction were eligible provided they fulﬁ lled 
the following criteria: either current statin use or clear 
indication for this treatment (and no clear indication for 
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folic acid); total cholesterol of at least 3∙5 mmol/L if 
already on a statin or 4∙5 mmol/L if not; and no clear 
contraindications to the study treatments.11 Individuals 
with other predominant medical problems that could 
reduce compliance with long-term study treatment were 
also excluded. (As well as comparing diﬀ erent doses of 
simvastatin, a two-by-two factorial design allowed the 
separate assessment of folate-based homocysteine-
lowering therapy.13)
Medical collaborators from 88 UK hospitals appointed 
senior nurses to run special clinics for the study (see 
Acknowledgments). Ethics committee approval was 
obtained from the South East Thames multicentre 
research ethics committee, along with local site-speciﬁ c 
approval. Computerised hospital records were used to 
identify patients discharged previously with a diagnosis 
of myocardial infarction who, with the agreement of their 
general practitioners, were invited to attend the local 
study clinic. At the initial screening visit, eligible 
individuals were given detailed information about the 
study and asked for their written agreement to partici-
pate. Potentially eligible participants entered a pre-
random isation run-in phase14 of treatment with 20 mg 
simvastatin daily (and placebo vitamins); they were 
instructed to stop taking any non-study statin.
Randomisation and masking
Compliant individuals who did not have a serious 
problem during the run-in, and agreed to participate, 
were randomly allocated to receive either 80 mg or 20 mg 
simvastatin daily with a double-dummy approach to 
mask the treatment allocation (and separately, in a two-
by-two factorial design, 2 mg folic acid plus 1 mg 
vitamin B12 daily or matching placebo). The central 
telephone randomisation system used a minimisation 
algorithm15 to balance the treatment groups with respect 
to eligibility criteria and other major prognostic factors.11 
Procedures
After randomisation between September 1998, and 
October 2001, participants were to be seen in study clinics 
at 2, 4, 8, and 12 months and then 6-monthly until ﬁ nal 
follow-up visits between October 2007, and June 2008. 
Those who became unable or unwilling to attend were to 
be contacted by telephone at the time of their scheduled 
follow-up (or, alternatively, follow-up was to be maintained 
via their general practitioner), but their allocated study 
simvastatin had to be stopped since blood safety monitoring 
could not be continued. Compliance with study treatment 
was assessed by review of the calendar-packed tablets 
remaining. For those who had stopped, the reasons for 
doing so were sought. Participants prescribed a non-study 
statin by their own doctor had the study simvastatin tablets 
stopped. To assess the eﬀ ects of the simvastatin allocation 
on lipid proﬁ le, assays were done in blood from a sample 
of about 1000 participants each year, from all participants 
scheduled for follow-up between February and November 
2003 (median of 2∙5 years), and at all ﬁ nal visits. Diﬀ erences 
in lipid concentrations were based on comparisons 
between all participants allocated 80 mg simvastatin and 
all allocated 20 mg simvastatin, irrespective of compliance 
(with any missing data imputed from the current use of 
study or non-study statin and the lipid concentrations 
following run-in on 20 mg simvastatin daily).
Information was recorded at each follow-up about any 
suspected myocardial infarction, stroke, vascular 
procedure, pulmonary embolus, cancer, or other serious 
adverse event (including all hospital admissions). 
Additionally, reports were systematically sought of muscle 
pain or weakness and of any serious or non-serious 
adverse events thought likely to be due to study treatment. 
Further details were sought from participants’ general 
practitioners (plus hospital records when necessary) 
about reports that might relate to major vascular events or 
deaths, and from the Medical Research Information 
Service for England and Wales and the General Register 
Oﬃ  ce for Scotland about the sites of any registered 
cancers and the certiﬁ ed causes of any deaths. All such 
information was reviewed by coordinating centre 
clinicians masked to study treatment allocation, and 
events coded according to prespeciﬁ ed criteria.11 Analyses 
were based on conﬁ rmed plus unrefuted reports; deﬁ nite 
conﬁ rmation was available for 93% of non-fatal myocardial 
infarctions, 89% of non-fatal strokes, and 96% of 
revascularisations included. 
Blood samples were taken at each follow-up visit for 
central laboratory assays of alanine aminotransferase and 
creatine kinase concentrations. Persistent increases in 
83 237 invited to participate 
15 590 not eligible or refused
34 780 attended screening 
6033 assigned 20 mg simvastatin
5975 (99·0%) with complete follow-up
7126 not eligible or withdrew
58 lost to follow-up for
      mortality 4 (0·1%)
      morbidity 56 (0·9%)
6031 assigned 80 mg simvastatin
5970 (99·0%) with complete follow-up
61 lost to follow-up for
      mortality 6 (0·1%)
      morbidity 60 (1·0%)
19 190 entered run-in phase
12 064 randomised
Figure 1: Trial proﬁ le 
Numbers lost to follow-up relate to those without information to the end of the scheduled treatment period for 
mortality (as well as morbidity) and for morbidity alone.
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alanine aminotransferase concentration to more than 
three times the upper limit of normal (deﬁ ned as two 
consecutive values) resulted in temporary discontinuation 
of study simvastatin and early follow-up visits according to 
a prespeciﬁ ed algorithm. Increases of creatine kinase to 
more than ﬁ ve times the upper limit of normal were 
followed by a repeat measurement within a week and a 
diagnosis of myopathy made if the concentration was more 
than ten times the upper limit of normal plus unexplained 
muscle symptoms. Rhabdomyolysis (a subset of myopathy) 
was deﬁ ned as creatine kinase more than 40 times the 
upper limit of normal plus evidence of end-organ damage 
(eg, doubling of plasma creatinine). Patients with 
conﬁ rmed myopathy had their study treatment 
permanently stopped. During the study, we observed that 
smaller increases in creatine kinase combined with raised 
alanine aminotransferase values often occurred before 
development of myopathy. Hence, incipient myopathy was 
retrospectively deﬁ ned as creatine kinase more than both 
three times the upper limit of normal and ﬁ ve times the 
participant’s baseline value plus alanine aminotransferase 
more than 1·7 times their baseline value.12
Statistical analysis
The data analysis plan was prespeciﬁ ed either in the 
original protocol or in amendments made before any 
analyses of the eﬀ ects on clinical outcomes were available 
to the steering committee (see study website and reference 
11). In planning the trial, it had been anticipated that 
allocation to 80 mg versus 20 mg simvastatin daily would 
produce an average 0∙5 mmol/L diﬀ erence in LDL 
cholesterol,16,17 which might produce a 10–15% further 
reduction in the rate of major coronary events (deﬁ ned 
as coronary death, myocardial infarction, or coronary 
revascularisation).18 On the basis of previous studies,18,19 
we estimated that about 1900 such events would occur 
during median follow-up of about 4 years, which would 
provide 90% power at p<0∙01 to detect a 15% risk 
reduction. The protocol prespeciﬁ ed that the steering 
committee could modify the study schedule on the basis 
of interim review of the unmasked cholesterol diﬀ erences 
between the treatment groups and of the masked event 
rates in both treatment groups combined. During 
median follow-up of 3–4 years, both the LDL cholesterol 
diﬀ erence between the treatment groups and the overall 
major coronary event rate were smaller than had been 
anticipated. Consequently, in 2004, the steering 
committee decided to change the primary outcome from 
major coronary events to major vascular events (deﬁ ned 
as coronary death, myocardial infarction, any stroke, or 
any arterial revascularisation), and to continue until at 
least 2800 patients had a major vascular event to have 
90% power at p<0∙05 to detect a 10% risk reduction.11  
Secondary outcomes were: major vascular events 
considered separately in the ﬁ rst year (when little 
diﬀ erence was anticipated)3 and in the later years of the 
scheduled treatment period; major vascular events in 
participants subdivided into three similar-sized groups 
with respect to LDL cholesterol concentrations following 
run-in on 20 mg simvastatin daily (with the hypothesis 
that a greater LDL cholesterol may produce a greater risk 
reduction); major vascular events in the presence and the 
absence of the allocated study vitamins (expecting that 
the eﬀ ects would be similar); major coronary events; and 
any type of stroke (excluding transient ischaemic attacks). 
Tertiary outcomes included: total and cause-speciﬁ c 
mortality (considering deaths from vascular and non-
vascular causes separately); vascular mortality excluding 
the ﬁ rst year after randomisation; coronary and non-
coronary revascular isation; conﬁ rmed haemorrhagic and 
other strokes separately; pulmonary embolus; total and 
site-speciﬁ c cancers; admissions to hospital for various 
other causes; and possible adverse eﬀ ects of treatment 
(in particular, evidence of liver or muscle abnormalities).
Comparisons involved log-rank analyses of the ﬁ rst 
occurrence of particular events during the scheduled 
treatment period among all participants allocated 80 mg 
simvastatin daily versus all allocated 20 mg simvastatin 
daily (ie, intention to treat),20,21 except risk ratios for 
myopathy, which were estimated by Cox regression. Tests 
for heterogeneity or, if more appropriate, trend were to 
be used to help to establish whether the proportional 
eﬀ ects noted in subcategories diﬀ ered clearly from overall 
Patients allocated 80 mg simvastatin daily Patients allocated 20 mg simvastatin daily
All Compliant Other* All Compliant Other*
12 months 5832 5275 (90%) 273 (5%) 5815 5273 (91%) 296 (5%)
24 months 5642 4939 (88%) 431 (8%) 5634 4863 (86%) 528 (9%)
36 months 5455 4666 (86%) 535 (10%) 5440 4506 (83%) 718 (13%)
48 months 5321 4425 (83%) 669 (13%) 5305 4199 (79%) 917 (17%)
60 months 5126 4160 (81%) 753 (15%) 5143 3902 (76%) 1053 (20%)
72 months 4895 3909 (80%) 790 (16%) 4901 3541 (72%) 1153 (24%)
84 months 3325 2555 (77%) 640 (19%) 3252 2243 (69%) 882 (27%)
Data are number of patients (%); percentages are proportion of patients at each follow-up. *Non-compliant with study 
simvastatin, but taking non-study statin.
Table 1: Compliance with study simvastatin (>80% taken) at scheduled follow-up visits
80 mg simvastatin daily 
(n=6031)
20 mg simvastatin daily 
(n=6033)
Medical advice* 663 (11·0%) 1105 (18·3%)
Other personal wish† 736 (12·2%) 801 (13·3%)
Raised liver or muscle enzyme concentrations 104 (1·7%) 30 (0·5%)
Muscle pain or weakness 63 (1·0%) 34 (0·6%)
Contraindicated drug started 19 (0·3%) 20 (0·3%)
Other symptoms 92 (1·5%) 100 (1·7%)
Other reasons 106 (1·8%) 96 (1·6%)
Total 1654 (27·4%) 2060 (34·1%)
Data are number of patients (%). *Non-study statin was started in 92% of the participants who stopped because of 
medical advice. †Other personal wish excludes discontinuations that were also attributed to medical advice.
Table 2: Reasons for stopping study simvastatin tablets before scheduled end of study
For the study protocol see 
www.searchinfo.org
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eﬀ ects after due allowance for multiple comparisons.20,22 
In-house software was used for all analyses. 
This study is registered, number ISRCTN74348595.
Role of the funding source
The study was designed, undertaken, analysed, interpreted, 
and reported by the investigators independently of all 
funding sources. The writing committee had full access to 
all the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Invitations were sent to 83 237 potentially eligible survivors 
of myocardial infarction, of whom 34 780 attended the 
initial screening clinic visit, and 19 190 entered the 
prerandomisation run-in phase (ﬁ gure 1). Reasons for 
withdrawal of the 7126 patients who entered the run-in but 
were not subsequently randomised have been reported 
previously;11 none had a serious adverse reaction or was 
excluded because of increases in liver or muscle enzyme 
concentrations. 12 064 individuals (10 012 men and 
2052 women) with a history of myocardial infarction and 
an average age of 64∙2 (SD 8∙9) years, were randomly 
assigned to treatment groups. Previous coronary 
revascularisation was reported by 3962 participants (33%), 
non-coronary revascularisation by 279 (2%), 
cerebrovascular disease (stroke or transient ischaemic 
attack) by 837 (7%), diabetes by 1267 (11%), and treated 
hypertension by 5074 (42%). Nearly three-quarters were 
taking a statin before study entry: simvastatin, 
5240 participants (43%); atorvastatin, 1563 (13%); 
pravastatin, 969 (8%); cerivastatin, 569 (5%); or ﬂ uvastatin, 
347 (3%). At the end of the run-in on 20 mg simvastatin 
daily, mean non-fasting total cholesterol was 4∙23 (SD 0∙73) 
mmol/L, directly measured LDL cholesterol was 
2∙50 (0∙61) mmol/L, HDL cholesterol was 1∙04 (0∙36) 
mmol/L, apolipoprotein A1 was 1∙35 (0∙22) g/L, and 
apolipoprotein B was 0∙90 (0∙17) g/L. The large study size 
and use of minimised randomisation produced good 
balance between the treatment groups. 
Figure 2: Eﬀ ects of simvastatin dose allocation on ﬁ rst major vascular event 
Analyses are of the numbers of participants having a ﬁ rst event of each type during follow-up (with non-fatal and fatal events considered separately), so there is some 
non-additivity between diﬀ erent types of event. Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants 
allocated 20 mg simvastatin, along with 95% CIs. The dashed vertical line shows the overall risk ratio. MI=myocardial infarction. CHD=coronary heart disease.
Simvastatin allocation Risk ratio (95% CI) p value
Non-fatal MI 
Coronary revascularisation
CHD death
Major coronary event
Non-fatal stroke
Fatal stroke
Total stroke
Non-coronary revascularisation
Major vascular event
397 (6·6%)
570 (9·5%)
447 (7·4%)
1189 (19·7%)
209 (3·5%)
57 (0·9%)
255 (4·2%)
144 (2·4%)
1477 (24·5%)
463 (7·7%)
610 (10·1%)
439 (7·3%)
1225 (20·3%)
230 (3·8%)
67 (1·1%)
279 (4·6%)
186 (3·1%)
1553 (25·7%)
80 mg daily 
(n=6031)
20 mg daily 
(n=6033)
Favours 80 mg daily Favours 20 mg daily
0·6 0·8 1·0 1·2 1·4
0·96 (0·89–1·04)
0·91 (0·77–1·08)
0·94 (0·88–1·01)
0·37
0·30
0·10
Total cholesterol 
(mmol/L)
LDL cholesterol 
(mmol/L)
HDL cholesterol 
(mmol/L)
Triglycerides 
(mmol/L)
Apolipoprotein A1 
(g/L)
Apolipoprotein B 
(g/L)
2 months –0·63 (0·07) –0·51 (0·06) –0·02 (0·04) –0·22 (0·11) –0·029 (0·022) –0·127 (0·016)
12 months –0·45 (0·08) –0·39 (0·06) 0·02 (0·04) –0·18 (0·11) 0·013 (0·023) –0·100 (0·018)
24 months –0·39 (0·03) –0·34 (0·02) 0·02 (0·01) –0·15 (0·04) 0·031 (0·023) –0·102 (0·017)
36 months –0·43 (0·03) –0·38 (0·03) 0·04 (0·01) –0·18 (0·04) 0·007 (0·021) –0·090 (0·017)
48 months –0·37 (0·07) –0·33 (0·06) 0·05 (0·03) –0·17 (0·10) 0·010 (0·021) –0·100 (0·018)
60 months –0·30 (0·07) –0·29 (0·06) 0·04 (0·03) –0·17 (0·08) 0·011 (0·019) –0·068 (0·018)
72 months –0·35 (0·05) –0·30 (0·05) –0·00 (0·03) –0·04 (0·08) 0·004 (0·017) –0·073 (0·013)
84 months –0·39 (0·03) –0·34 (0·02) 0·02 (0·02) –0·17 (0·04) –0·005 (0·009) –0·084 (0·007)
Average –0·40 (0·01) –0·35 (0·01) 0·02 (0·01) –0·15 (0·02) 0·002 (0·005) –0·087 (0·004)
Data are mean (SE); diﬀ erences for the 80 mg simvastatin group minus those for the 20 mg group. Comparison is by intention to treat, with any missing data imputed. At 2, 
12, 24, 36, 48, 60, 72, and 84 months, the numbers of patients (including those with imputed values) contributing to total, LDL, and HDL cholesterol and triglycerides were 
439, 412, 3337, 2812, 709, 576, 779, and 2924, and to apolipoproteins were 437, 412, 494, 557, 550, 576, 779, and 2924.
Table 3: Mean diﬀ erences in plasma concentrations of lipids during follow-up, by allocated treatment
Articles
1662 www.thelancet.com   Vol 376   November 13, 2010
Mean follow-up duration was 6∙7 (SD 1∙5) person-years: 
40 129 person-years in those allocated 80 mg and 40 158 
person-years in those allocated 20 mg simvastatin daily. 
Compliance was deﬁ ned as at least 80% of the scheduled 
simvastatin tablets having been taken since the previous 
follow-up. Among participants allocated 80 mg 
simvastatin, 5275 (90%) were compliant after 12 months, 
and 2555 (77%) after 84 months (table 1). Compliance in 
patients allocated 20 mg simvastatin was similar after 
12 months, but had dropped to 69% by 84 months, with 
an increasing proportion of patients having started a non-
study statin. Table 2 shows that the main reason for 
discontinuation of study treatment in participants 
allocated 20 mg simvastatin was medical advice, generally 
because of a perceived need for more intensive cholesterol-
lowering therapy. By contrast, slightly more of the patients 
allocated 80 mg simvastatin were likely to stop because of 
raised liver or muscle enzyme concentrations or to have 
reported muscle pain or weakness. 
Table 3 shows the blood lipid diﬀ erences achieved 
between participants allocated 80 mg versus 20 mg 
simvastatin. At 2 months, LDL cholesterol was reduced 
by 0∙51 (SE 0∙06) mmol/L more in those allocated 80 mg 
simvastatin (as originally anticipated), but that diﬀ erence 
had decreased to 0∙34 (0∙02) mmol/L by 84 months 
(mainly because of increasing non-compliance with the 
allocated treatment), yielding a weighted average 
diﬀ erence during the study of 0∙35 (0∙01) mmol/L. In 
parallel, apolipoprotein B concentrations were 
signiﬁ cantly reduced by a weighted average of 0∙087 
(0∙004) g/L. No signiﬁ cant diﬀ erences were observed in 
HDL cholesterol or apolipoprotein A1, but non-fasting 
triglycerides were reduced by a weighted average of 0∙15 
(0∙02) mmol/L. The intention-to-treat analyses of the 
eﬀ ects of treatment allocation on clinical outcomes 
should be interpreted in light of the achieved 0∙35 mmol/L 
average diﬀ erence in LDL cholesterol. 
Major vascular events occurred during the scheduled 
treatment period in 1477 (24·5%) of the 6031 participants 
allocated 80 mg simvastatin versus 1553 (25·7%) of the 
6033 allocated 20 mg simvastatin (risk ratio [RR] 0∙94, 
95% CI 0∙88–1∙01; p=0∙10; ﬁ gure 2). This non-signiﬁ cant 
reduction in risk did not increase signiﬁ cantly with 
duration of treatment (p value for trend=0∙7; ﬁ gure 3). 
Among participants in the low, middle, and high thirds of 
baseline LDL cholesterol (ﬁ gure 4), allocation to 80 mg 
simvastatin produced further average reductions in LDL 
cholesterol of 0∙30 (SE 0∙02), 0∙37 (0∙02), and 0∙36 (0∙02) 
mmol/L, respectively, but no signiﬁ cant diﬀ erence 
between the major vascular event reductions. Nor were 
there any signiﬁ cant diﬀ erences in the eﬀ ects of more 
intensive lowering of LDL cholesterol on major vascular 
events in any other subcategories examined (ﬁ gure 4), 
including in the presence of the allocated vitamins 
(11% [SE 4∙8] reduction) and in their absence (1% [5∙2] 
reduction; heterogeneity p value=0∙15).
Compared with 20 mg simvastatin, allocation to 80 mg 
simvastatin was associated with proportional reduct ions in 
major coronary events of 4% (SE 4), in any stroke of 9% (8), 
and in non-coronary revascularisations of 23% (10; ﬁ gure 2). 
The overall eﬀ ect on major coronary events reﬂ ect ed the 
combination of RRs of 0∙85 (95% CI 0∙75–0∙99) for non-
fatal myocardial infarction, 0∙93 (0·83–1·04) for coronary 
revascularisation, and 1∙02 (0∙89–1∙16) for coronary death. 
The eﬀ ect on any stroke reﬂ ected RRs of 0∙91 (0∙75–1∙10) 
for non-fatal stroke and of 0∙85 (0∙60–1∙21) for fatal 
stroke, with no apparent eﬀ ect on deﬁ nite haemorrhagic 
stroke (24 [0·4%] vs 25 [0·4%]) and RR of 0∙91 (0∙77–1∙09) 
for the residual of presumed ischaemic stroke (233 [3·9%] 
vs 255 [4·2%]). For other vascular outcomes, there were no 
clear eﬀ ects on the numbers of patients admitted to 
hospital for stable or unstable angina (743 [12·3%] allocated 
80 mg simvastatin vs 718 [11·9%] allocated 20 mg 
simvastatin), admission to hospital or died because of 
heart failure (254 [4·2%] vs 254 [4·2%]), or reported to have 
had transient cerebral ischaemic attacks (154 [2·6%] vs 
151 [2·5%]) or non-fatal or fatal pulmonary emboli 
(59 [1·0%] vs 53 [0·9%]).
Figure 3: Eﬀ ects of simvastatin dose allocation on ﬁ rst major vascular event by year of follow-up
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. 
The dashed vertical line shows the overall risk ratio. Analyses are of numbers of participants having a ﬁ rst event during each year of follow-up and of those still at risk 
of a ﬁ rst event at the start of each year.
Simvastatin allocationYear of follow-up Risk ratio (95% CI) p value
1
2
3
4
5
6
7+
All follow-up
χ2 for trend=0·15 (p=0·7)
 232/6031 (3·8%)
 224/5782 (3·9%)
 202/5519 (3·7%)
 195/5257 (3·7%)
 202/5012 (4·0%)
 193/4741 (4·1%)
 229/4463 (5·1%)
 1477/6031 (24·5%)
 261/6033 (4·3%)
 233/5752 (4·1%)
 227/5474 (4·1%)
 191/5201 (3·7%)
 211/4955 (4·3%)
 207/4687 (4·4%)
 223/4404 (5·1%)
 1553/6033 (25·7%)
80 mg daily 20 mg daily 
Favours 80 mg daily Favours 20 mg daily
0·94 (0·88–1·01) 0·10
0·6 0·8 1·0 1·2 1·4
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The numbers of deaths attributed to vascular causes 
(565 [9·4%] vs 572 [9·5%]) or non-vascular causes 
(399 [6·6%] vs 398 [6·6%]; ﬁ gure 5) did not diﬀ er 
signiﬁ cantly between the treatment groups. Among the 
vascular deaths, allocation to more intensive therapy was 
associated with fewer deaths due to deﬁ nite acute 
myocardial infarction (RR 0∙84; 95% CI 0∙68–1∙03), but 
that diﬀ erence was not signiﬁ cant and there was no 
apparent reduction in deaths from all other vascular 
causes. Among the non-vascular deaths, there were no 
signiﬁ cant diﬀ erences in the numbers attributed to 
neoplastic, respiratory, other medical (including 
11 vs four hepatic and three vs seven renal) or non-medical 
(including one vs two from suicide) causes. 
Figure 4: Eﬀ ects of simvastatin dose allocation on ﬁ rst major vascular event in diﬀ erent categories of participant
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. 
The dashed vertical line shows the overall risk ratio. p values of χ2 tests are given for heterogeneity between RRs within dichotomous categories and for trend within 
other categories (except for previous disease categories since there is some overlap between them). Lipid categories relate to measured values at the randomisation 
visit after all participants had been taking 20 mg simvastatin daily for 2 months during the run-in. MI=myocardial infarction. CHD=coronary heart disease. GFR 
(MDRD)=glomerular ﬁ ltration rate estimated with modiﬁ cation of diet in renal disease equation.
Simvastatin allocationBaseline characteristic Heterogeneity or
trend p value
Prior disease
MI alone
+Other CHD
+Other vascular
+Diabetes mellitus
Sex
Male
Female
Age (years)
<60
≥60 to <70
≥70
Total cholesterol (mmol/L)
<4·0
≥4·0 to <4·5
≥4·5
LDL cholesterol (mmol/L)
<2·2
≥2·2 to <2·7
≥2·7
HDL cholesterol (mmol/L)
<0·9
≥0·9 to <1·1
≥1·1
Triglycerides (mmol/L)
<1·3
≥1·3 to <2·0
≥2·0
Smoking status
Never smoked
Ex-smoker
Current smoker
Treated hypertension
No
Yes
Estimated GFR (MDRD) (mL/min)
<60
≥60
All patients
 
 656/2955 (22·2%)
 631/2484 (25·4%)
           164/524 (31·3%)
 225/633 (35·5%)
 1277/5005 (25·5%)
 200/1026 (19·5%)
 406/1880 (21·6%)
 574/2414 (23·8%)
 497/1737 (28·6%)
 610/2460 (24·8%)
 392/1645 (23·8%)
 475/1926 (24·7%)
 473/1975 (23·9%)
 474/2015 (23·5%)
 530/2041 (26·0%)
 580/2238 (25·9%)
 385/1516 (25·4%)
 512/2277 (22·5%)
 480/2022 (23·7%)
 462/1878 (24·6%)
 535/2131 (25·1%)
 329/1373 (24·0%)
 940/3918 (24·0%)
 208/740 (28·1%)
 811/3495 (23·2%)
 666/2536 (26·3%)
 265/820 (32·3%)
 1212/5211 (23·3%)
 1477/6031 (24·5%)
                           669/2890 (23·1%)
 658/2557 (25·7%)
 205/538 (38·1%)
 245/634 (38·6%)
 1325/5007 (26·5%)
 228/1026 (22·2%)
 424/1885 (22·5%)
 601/2414 (24·9%)
 528/1734 (30·4%)
 617/2397 (25·7%)
 442/1721 (25·7%)
 494/1915 (25·8%)
 503/1958 (25·7%)
 478/2012 (23·8%)
 572/2063 (27·7%)
 652/2320 (28·1%)
 378/1446 (26·1%)
 523/2267 (23·1%)
 492/1977 (24·9%)
 490/1860 (26·3%)
 571/2196 (26·0%)
 320/1370 (23·4%)
 997/3920 (25·4%)
 236/743 (31·8%)
 847/3495 (24·2%)
 706/2538 (27·8%)
 292/866 (33·7%)
 1261/5167 (24·4%)
 1553/6033 (25·7%)
80 mg daily 20 mg daily 
Favours 80 mg daily Favours 20 mg daily
NA
0·40
0·86
0·98
0·86
0·45
0·86
0·20
0·78
0·94
0·6 0·8 1·0 1·2 1·4
Risk ratio and 95% CI
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New primary cancers (excluding non-melanoma skin 
cancer) were diagnosed in 640 (10·6%) participants 
allocated 80 mg simvastatin versus 677 (11·2%) allocated 
20 mg simvastatin (RR 0∙95, 95% CI 0∙85–1·06; ﬁ gure 6), 
and caused death in 246 (4·1%) versus 266 (4·4%) 
participants (0∙93, 0·78–1·10; ﬁ gure 5). These diﬀ erences 
were not signiﬁ cant, and nor were there signiﬁ cant 
diﬀ erences between the treatment groups in the 
incidence of cancers in any particular body system. When 
cancer sites were more ﬁ nely divided, a nominally 
signiﬁ cant excess of female breast cancer was observed 
(31 [3·0%] vs 17 [1·7%]; along with four vs one male breast 
cancers), but that diﬀ erence is based on small numbers 
of events and was not signiﬁ cant after appropriate 
allowance was made for multiple comparisons (as 
prespeciﬁ ed). Moreover, the Cholesterol Treatment 
Trialists’ updated meta-analysis of individual patient data 
does not indicate any excess risk of female breast cancer 
in the other trials of statin versus control (194 [1∙0%] 
vs 187 [1∙0%]) or of more intensive versus standard statin 
regimens (42 [1∙5%] vs 37 [1∙3%]).23
Persistent increases of alanine aminotransferase to 
four times the upper limit of normal were rare, and no 
signiﬁ cant diﬀ erence was found between the treatment 
groups (14 [0·2%] allocated 80 mg simvastatin vs 
ten [0·2%] allocated 20 mg simvastatin; p=0·5; table 4). 
Only eight cases of hepatitis were reported (three vs ﬁ ve); 
all of these patients recovered, none had serious liver 
Figure 5: Eﬀ ects of simvastatin dose allocation on cause-speciﬁ c mortality 
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. 
The dashed vertical line shows the overall risk ratio. MI=myocardial infarction. CHD=coronary heart disease.
Simvastatin allocationCause of death Risk ratio (95% CI) p value
Acute MI
Other CHD
Other vascular
Any vascular
Neoplastic
Respiratory
Other medical
Non-medical
Any non-vascular
Any death
 162 (2·7%)
 285 (4·7%)
 118 (2·0%)
 565 (9·4%)
 246 (4·1%)
 75 (1·2%)
 65 (1·1%)
 13 (0·2%)
 399 (6·6%)
 964 (16·0%)
 193 (3·2%)
 246 (4·1%)
 133 (2·2%)
 572 (9·5%)
 266 (4·4%)
 58 (1·0%)
 61 (1·0%)
 13 (0·2%)
 398 (6·6%)
 970 (16·1%)
80 mg daily
(n=6031) 
20 mg daily
(n=6033) 
Favours 80 mg daily Favours 20 mg daily
1·00 (0·87–1·15) 0·96
0·99 (0·88–1·11) 0·84
0·99 (0·91–1·09) 0·90
0·6 0·8 1·0 1·2 1·4
Figure 6: Eﬀ ect of simvastatin dose allocation on site-speciﬁ c cancer incidence 
Risk ratios are plotted comparing outcomes in participants allocated 80 mg simvastatin with those in participants allocated 20 mg simvastatin, along with 95% CIs. 
The dashed vertical line shows the overall risk ratio. Analyses are of the numbers of participants developing cancer at each site (excluding recurrences or new cancers 
at the same site), so there is some non-additivity between cancers at diﬀ erent sites. Connective tissue includes breast, melanoma, skin, and other connective tissue 
cancers, but not non-melanoma skin cancer (which was prospectively to be considered separately).
Simvastatin allocationCancer site Risk ratio (95% CI)
Gastrointestinal
Respiratory and intrathoracic
Connective tissue
Genitourinary
CNS
Haematological
Other
Not speciﬁed
Any cancer
Non-melanoma skin
 141 (2·3%)
 123 (2·0%)
 70 (1·2%)
 220 (3·6%)
 8 (0·1%)
 80 (1·3%)
 15 (0·2%)
 27 (0·4%)
 640 (10·6%)
 207 (3·4%)
 161 (2·7%)
 143 (2·4%)
 53 (0·9%)
 247 (4·1%)
 11 (0·2%)
 64 (1·1%)
 12 (0·2%)
 38 (0·6%)
 677 (11·2%)
 228 (3·8%)
80 mg daily
(n=6031) 
20 mg daily
(n=6033) 
Favours 80 mg daily Favours 20 mg daily
0·95 (0·85–1·06) 
0·6 0·8 1·0 1·2 1·4
p value
0·32
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disease, and no deaths from hepatitis were reported. At 
each of the scheduled follow-up visits, about 7% of the 
participants reported unexplained muscle pain or 
weakness, but at no time was there any signiﬁ cant 
diﬀ erence between the treatment groups. Similarly, at 
each scheduled follow-up in the Heart Protection Study 
of 40 mg simvastatin daily versus placebo, 6–7% of 
participants in each treatment group reported such 
symptoms.4 There was, however, a small excess in reports 
of such symptoms on at least one occasion during follow-
up (43·5% allocated 80 mg vs 41·6% allocated 20 mg 
simvastatin; p=0·05). 
Few of the participants were ever found to have raised 
creatine kinase, but there was an excess in those allocated 
80 mg simvastatin (table 4). Myopathy was conﬁ rmed 
in 53 (1%) participants allocated 80 mg simvastatin 
compared with two (0·03%) allocated 20 mg simvastatin 
(RR 26·6, 95% CI 6·5–109·3; p<0·0001). This excess was 
highest in the ﬁ rst year after allocation to 80 mg simvastatin 
daily (four per 1000 person-years) and decreased in 
subsequent years (one per 1000 person-years). During the 
study, an increased risk of myopathy (based on eight cases) 
was found when 80 mg simvastatin daily was used in 
combination with amiodarone12,24 so, in January, 2003, all 
patients taking concurrent amiodarone were provided 
with 20 mg simvastatin daily (irrespective of their original 
allocation). Incipient myopathy was also detected in 
82 (1·4%) participants allocated 80 mg simvastatin 
compared with 12 (0·2%) allocated 20 mg simvastatin 
(RR 6·9, 95% CI 3·8–12·6; p<0·0001). Participants with 
incipient myopathy were generally asymptomatic, and 
many remained on their study simvastatin; 12 (21%) of the 
58 who kept taking the drug (52 allocated 80 mg vs six 
allocated 20 mg), but only one (3%) of the 36 who stopped 
(all on 80 mg simvastatin daily), subsequently developed 
deﬁ nite myopathy. Consequently, if some of these patients 
had not stopped their study simvastatin, the rate of deﬁ nite 
myopathy would have been somewhat greater than is 
shown in table 4. 
Rhabdomyolysis was diagnosed in seven participants 
allocated 80 mg simvastatin versus none allocated 20 mg 
simvastatin. But, for another seven participants with 
creatine kinase higher than 40 times the upper limit of 
normal (all on 80 mg simvastatin), no information was 
available about end-organ damage, so rhabdomyolysis 
could not be conﬁ rmed or refuted. Consequently, the 
number of conﬁ rmed cases might underestimate the 
incidence of rhabdomyolysis with 80  mg simvastatin 
daily. All of the patients with myopathy recovered, 
although ten were admitted to hospital with (or at the 
time of) myopathy and two died within a few weeks of 
developing the disorder (one from heart failure, with 
rhabdomyolysis given as a contributory cause on the 
death certiﬁ cate; and one from septicaemia with no 
mention of rhabdomyolysis).
Rates of admission to hospital for other outcomes did 
not diﬀ er signiﬁ cantly between the treatment groups 
(even before making allowance for the exploratory nature 
of such analyses). New diabetes was reported by 
625 (11·6%) participants allocated 80 mg simvastatin 
versus 587 (10·9%) allocated 20 mg simvastatin (RR 1·07, 
95% CI 0·95–1·19). Full blood counts were done at 
randomisation and at 1-year and 4-year follow-up visits, 
with a signiﬁ cant eﬀ ect (p<0·0001) seen only for platelet 
count (219×10³ [SD 58] vs 223×10³ [59] cells per μL at 
4 years). This small diﬀ erence of 4·5×10³ (SE 1·2) per μL 
did not seem to be clinically signiﬁ cant, with only four 
versus two reports of thrombocytopenia. Blood pressure at 
the ﬁ nal follow-up visit did not diﬀ er between the 
treatment groups. Since age-related hearing loss has been 
associated with vascular risk factors,25–27 hearing thresholds 
at 1 and 4 kHz were assessed28 in both ears at the ﬁ nal 
follow-up visit. Hearing thresholds increased with age at 
both the low and high frequencies, but there was no 
measurable eﬀ ect at either frequency of the small 
additional LDL reduction produced by 80 mg simvastatin 
daily. Apart from the diﬀ erences in study treatment 
discontinuations attributed to the perceived need for more 
intensive cholesterol-lowering therapy or to muscle 
problems, there were no signiﬁ cant diﬀ erences attributed 
to any other adverse event (191 [3·2%] vs 187 [3·1%]; 
table 2). 
Discussion
In an updated meta-analysis,23 the proportional reduction 
in the risk of major vascular events per 1 mmol/L LDL 
cholesterol reduction in the trials of more versus less 
intensive therapy was similar to that seen in the trials of 
statin versus control and, in the combined data from all of 
these trials, the proportional risk reduction was 22% 
80 mg simvastatin 
daily (n=6031)
20 mg simvastatin 
daily (n=6033)
Alanine aminotransferase
>2  to ≤4 times ULN 197 (3·3%) 119 (2·0%)
>4 times ULN 51 (0·8%) 40 (0·7%)
>4 times ULN on repeat visits 14 (0·2%) 10 (0·2%)
Creatine kinase 
>5 to ≤10 times ULN 77 (1·3%) 31 (0·5%)
>10 to ≤40 times ULN * 45 (0·7%) 12 (0·2%)
>40 times ULN * 23 (0·4%) 0 
Myopathy
Incipient 82 (1·4%) 12 (0·2%)
Deﬁ nite† 53 (0·9%) 2 (0·0%)
No rhabdomyolysis 46 (0·8%) 2 (0·0%)
Rhabdomyolysis 7 (0·1%) 0
Data are number of patients (%).ULN=upper limit of normal for laboratory. 
*20 (vs 11) patients with creatine kinase more than ten times ULN were 
asymptomatic (and so not classiﬁ ed as myopathy). †Five (vs one) of the patients 
with deﬁ nite myopathy did not have a recorded measurement of creatine kinase 
more than ten times ULN, but presented with clinical myopathy.
Table 4: Myopathy and raised alanine aminotransferase and creatine 
kinase concentrations
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(95% CI 20–24) per 1 mmol/L LDL cholesterol reduction. 
Although not signiﬁ cant on its own, the 6% (SE 3·5) 
proportional risk reduction in the SEARCH trial that was 
associated with a 0·35 mmol/L decrease in LDL 
cholesterol is compatible with the 7% reduction (ie, one 
third of 22%) expected on the basis of previous trials. 
Collectively, these results are consistent with a direct 
association between the achieved reductions in LDL 
cholesterol and the proportional reductions in major 
vascular events. In particular, the proportional reduction 
in risk per 1 mmol/L reduction in LDL cholesterol seems 
to be largely independent of the presenting cholesterol 
concentration. That is, the results show that lowering of 
LDL cholesterol from 4 mmol/L to 3 mmol/L reduces risk 
of vascular events by about a ﬁ fth, and that lowering it 
from 3 mmol/L to 2 mmol/L also reduces the (residual) 
risk by about a ﬁ fth. 
Before SEARCH, the largest of the randomised trials of 
more versus less intensive statin therapy assessed the 
eﬀ ects of lowering LDL cholesterol from an average of 
2·6 mmol/L to an average of 2·0 mmol/L for up to 
6 years in 10 001 patients.7 More intensive therapy was 
associated with a signiﬁ cant 22% (95% CI 11–31) 
reduction in major vascular events, but concerns were 
raised by a non-signiﬁ cant excess of non-vascular deaths 
(158 [3·2%] on 80 mg atorvastatin vs 127 [2·5%] on 10 mg 
atorvastatin; RR 1·25; 95% CI 0·99–1·57; p=0·06). This 
adverse trend was not supported by a subsequent 
randomised comparison of 80 mg atorvastatin versus 
20–40 mg simvastatin for 5 years in 8888 patients 
(143 [3·2%] vs 156 [3·5%] non-vascular deaths; RR 0·92, 
95% CI 0·73–1·15; p=0·47).8 In the larger and longer 
SEARCH trial, LDL cholesterol was reduced from an 
average of 2·52 mmol/L to an average of 2·17 mmol/L 
for about 7 years and, again, there were similar numbers 
of non-vascular deaths in both groups (399 [6·6%] on 
80 mg simvastatin vs 398 [6·6%] on 20 mg simvastatin), 
as well as similar numbers with incident cancer (640 
[10·6%] vs 677 [11·2%]). The higher absolute rate of non-
vascular mortality in SEARCH reﬂ ects both the older age 
of the participants and the longer study duration. 
Randomised trials are not needed to identify large 
eﬀ ects on rare outcomes,22 and a higher than expected 
rate of myopathy was detected early in SEARCH.12 The 
absolute excess of myopathy was about four per 1000 
during the ﬁ rst year of treatment with 80 mg simvastatin 
daily, and decreased thereafter to about one per 1000 per 
year,12 with about a ﬁ fth developing rhabdomyolysis. 
About half of these cases were detected as a result of the 
frequent and systematic monitoring procedures in 
SEARCH. Such monitoring, and detection at an early 
stage of myopathy, might have prevented the 
development of some cases of rhabdomyolysis with 
severe organ damage. SEARCH allowed the 
identiﬁ cation of a common variant (estimated 
population prevalence of 0·15) in the SLCO1B1 gene 
that was associated with a particularly high risk of 
myopathy.12 More than 60% of the myopathy cases could 
be attributed to the C variant at this location in the 
gene, which aﬀ ects the coding of the organic anion-
transporter polypeptide OAT1B1 responsible for statin 
uptake into the liver. These ﬁ ndings suggest that, if 
80 mg simvastatin daily is to be prescribed, regular 
blood monitoring should be considered routinely to be 
able to detect early signs for the development of 
myopathy unless genetic testing can be used to identify 
individuals who are at low risk of myopathy. 
In the Heart Protection Study,4 average compliance of 
about two-thirds to allocated treatment with 40 mg 
simvastatin daily yielded an average reduction in LDL 
cholesterol of 1·0 mmol/L and a 24% proportional 
reduction in the risk of major vascular events. We 
anticipated that allocation to 20 mg simvastatin daily in 
the SEARCH study population would reduce LDL 
cholesterol by at least 1·0 mmol/L, and that allocation to 
80 mg simvastatin daily would reduce it by a further 
0·5 mmol/L. But, during follow-up, LDL cholesterol 
treatment targets for the management of coronary heart 
disease were reduced substantially. For example, when 
recruitment started in 1998, international guidelines 
generally advocated LDL cholesterol targets of about 
3 mmol/L, and the initiation of statin treatment only 
when the presenting LDL cholesterol was higher than 
about 2·5 mmol/L.29,30 After publication in 2002 of the 
Heart Protection Study results,4 which showed similar 
proportional reductions in risk in patients who presented 
with LDL cholesterol concentrations lower or higher than 
2·5 mmol/L, many guidelines were modiﬁ ed.31,32 
By 2005, LDL cholesterol targets had typically fallen to 
less than 2 mmol/L for the types of high-risk individual 
included in SEARCH.33 Moreover, the UK Government 
started to provide ﬁ nancial incentives to encourage the 
use of high doses of statin therapy for secondary 
prevention and, in 2008, recommended the use of 80 mg 
simvastatin daily for intensive LDL-cholesterol-lowering 
therapy.34 As a consequence, an increasing proportion 
of SEARCH participants had their allocated study 
simvastatin stopped and more intensive non-study 
regimens prescribed by their own doctors. This outcome 
was somewhat more likely to occur in patients allocated 
20 mg simvastatin (presumably because their measured 
lipid concentrations were higher) than in those allocated 
80 mg simvastatin. Consequently, whereas the LDL 
cholesterol diﬀ erence was 0·5 mmol/L at 2–4 months 
after randomisation (when there was good compliance 
and little non-study statin use), it had fallen to about 
0·3 mmol/L by the end of the scheduled treatment 
period, yielding a study-long average diﬀ erence of 
0·35 mmol/L. Even so, as shown here and in the 
accompanying paper,23 the results of SEARCH are 
consistent with previous statin trials and provide 
supporting evidence for the beneﬁ ts of intensive 
LDL-cholesterol-lowering therapy in patients at 
suﬃ  ciently high risk.
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After randomisation and long-term follow-up of large 
numbers of patients in trials of statin versus control 
and of more versus less intensive statin therapy 
(including SEARCH), there is clear evidence that 
lowering of LDL cholesterol concentrations lowers the 
risk of major vascular events and that intensive lowering 
of LDL cholesterol reduces risk more. The risk of statin-
related myopathy with 20–40 mg simvastatin daily is 
low (about one per 10 000 patients per year), but is 
increased about ten times (to about one per 1000 patients 
per year4,35) with 80 mg simvastatin daily. This excess 
risk tends to occur during the ﬁ rst year after study 
treatment (when monitoring could be focused) and is 
largely conﬁ ned to people who carry a particular genetic 
variant (which could be detected before starting 
treatment). Even so, for patients deemed to be at 
suﬃ  cient risk of major vascular events, a more 
appropriate strategy (by contrast with current guidance34) 
could be to consider regimens involving newer, more 
potent, statins (eg, 80 mg atorvastatin or 20–40 mg 
rosuvastatin daily) or the combination of standard doses 
of generic statins (eg, 40 mg simvastatin daily) 
with other agents that can lower LDL cholesterol 
substantially without producing such increases in the 
risk of myopathy.
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